Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 172.19
LCI's Cash to Debt is ranked higher than
87% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. LCI: 172.19 )
LCI' s 10-Year Cash to Debt Range
Min: 0.01   Max: No Debt
Current: 172.19

Equity to Asset 0.90
LCI's Equity to Asset is ranked higher than
94% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. LCI: 0.90 )
LCI' s 10-Year Equity to Asset Range
Min: -0.17   Max: 0.9
Current: 0.9

-0.17
0.9
Interest Coverage 677.61
LCI's Interest Coverage is ranked higher than
73% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. LCI: 677.61 )
LCI' s 10-Year Interest Coverage Range
Min: 1.15   Max: 677.61
Current: 677.61

1.15
677.61
F-Score: 7
Z-Score: 33.93
M-Score: -1.98
WACC vs ROIC
17.60%
78.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 52.74
LCI's Operating margin (%) is ranked higher than
98% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. LCI: 52.74 )
LCI' s 10-Year Operating margin (%) Range
Min: -119.46   Max: 46.27
Current: 52.74

-119.46
46.27
Net-margin (%) 34.24
LCI's Net-margin (%) is ranked higher than
97% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. LCI: 34.24 )
LCI' s 10-Year Net-margin (%) Range
Min: -73   Max: 28.64
Current: 34.24

-73
28.64
ROE (%) 41.79
LCI's ROE (%) is ranked higher than
98% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. LCI: 41.79 )
LCI' s 10-Year ROE (%) Range
Min: -38.23   Max: 117.18
Current: 41.79

-38.23
117.18
ROA (%) 36.72
LCI's ROA (%) is ranked higher than
99% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. LCI: 36.72 )
LCI' s 10-Year ROA (%) Range
Min: -28.9   Max: 50.98
Current: 36.72

-28.9
50.98
ROC (Joel Greenblatt) (%) 132.98
LCI's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. LCI: 132.98 )
LCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -162.82   Max: 107.31
Current: 132.98

-162.82
107.31
Revenue Growth (3Y)(%) 24.90
LCI's Revenue Growth (3Y)(%) is ranked higher than
93% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. LCI: 24.90 )
LCI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.6   Max: 48.4
Current: 24.9

-3.6
48.4
EBITDA Growth (3Y)(%) 152.30
LCI's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. LCI: 152.30 )
LCI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 152.3
Current: 152.3

0
152.3
» LCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

LCI Guru Trades in Q1 2014

Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Jim Simons 111,800 sh (-40.66%)
» More
Q2 2014

LCI Guru Trades in Q2 2014

Chuck Royce 338,400 sh (New)
Joel Greenblatt 35,709 sh (New)
Jim Simons Sold Out
» More
Q3 2014

LCI Guru Trades in Q3 2014

Paul Tudor Jones 28,221 sh (New)
Joel Greenblatt 303,345 sh (+749.49%)
Chuck Royce 427,410 sh (+26.3%)
» More
Q4 2014

LCI Guru Trades in Q4 2014

Joel Greenblatt 1,026,029 sh (+238.24%)
Chuck Royce 499,830 sh (+16.94%)
Paul Tudor Jones 31,436 sh (+11.39%)
» More
» Details

Insider Trades

Latest Guru Trades with LCI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 Add 238.24%0.25%$40.3 - $57.52 $ 62.434%1026029
Joel Greenblatt 2014-09-30 Add 749.49%0.12%$34.05 - $51.19 $ 62.457%303345
Joel Greenblatt 2014-06-30 New Buy0.02%$29.62 - $49.76 $ 62.459%35709
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.30
LCI's P/E(ttm) is ranked higher than
92% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.60 vs. LCI: 18.30 )
LCI' s 10-Year P/E(ttm) Range
Min: 12.33   Max: 185.79
Current: 18.3

12.33
185.79
Forward P/E 16.81
LCI's Forward P/E is ranked higher than
90% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. LCI: 16.81 )
N/A
PE(NRI) 18.20
LCI's PE(NRI) is ranked higher than
92% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.50 vs. LCI: 18.20 )
LCI' s 10-Year PE(NRI) Range
Min: 12.32   Max: 222.5
Current: 18.2

12.32
222.5
P/B 5.88
LCI's P/B is ranked higher than
61% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. LCI: 5.88 )
LCI' s 10-Year P/B Range
Min: 0.61   Max: 10.48
Current: 5.88

0.61
10.48
P/S 6.25
LCI's P/S is ranked higher than
66% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. LCI: 6.25 )
LCI' s 10-Year P/S Range
Min: 0.49   Max: 7.09
Current: 6.25

0.49
7.09
PFCF 33.02
LCI's PFCF is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 33.02 )
LCI' s 10-Year PFCF Range
Min: 3.21   Max: 342.5
Current: 33.02

3.21
342.5
POCF 23.73
LCI's POCF is ranked higher than
82% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. LCI: 23.73 )
LCI' s 10-Year POCF Range
Min: 2.86   Max: 577
Current: 23.73

2.86
577
EV-to-EBIT 10.54
LCI's EV-to-EBIT is ranked higher than
95% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. LCI: 10.54 )
LCI' s 10-Year EV-to-EBIT Range
Min: -114.7   Max: 687.5
Current: 10.54

-114.7
687.5
PEG 0.62
LCI's PEG is ranked higher than
98% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 0.62 )
LCI' s 10-Year PEG Range
Min: 0.15   Max: 77.25
Current: 0.62

0.15
77.25
Shiller P/E 75.95
LCI's Shiller P/E is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 103.75 vs. LCI: 75.95 )
LCI' s 10-Year Shiller P/E Range
Min: 21.37   Max: 358
Current: 75.95

21.37
358
Current Ratio 7.74
LCI's Current Ratio is ranked higher than
91% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. LCI: 7.74 )
LCI' s 10-Year Current Ratio Range
Min: 0.99   Max: 8.73
Current: 7.74

0.99
8.73
Quick Ratio 6.75
LCI's Quick Ratio is ranked higher than
91% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. LCI: 6.75 )
LCI' s 10-Year Quick Ratio Range
Min: 0.26   Max: 6.75
Current: 6.75

0.26
6.75
Days Inventory 155.45
LCI's Days Inventory is ranked higher than
70% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. LCI: 155.45 )
LCI' s 10-Year Days Inventory Range
Min: 68.82   Max: 174.73
Current: 155.45

68.82
174.73
Days Sales Outstanding 89.70
LCI's Days Sales Outstanding is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. LCI: 89.70 )
LCI' s 10-Year Days Sales Outstanding Range
Min: 34.69   Max: 171.98
Current: 89.7

34.69
171.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 15.88
LCI's Price/Net Cash is ranked higher than
90% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 15.88 )
LCI' s 10-Year Price/Net Cash Range
Min: 10.91   Max: 42.78
Current: 15.88

10.91
42.78
Price/Net Current Asset Value 9.71
LCI's Price/Net Current Asset Value is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 9.71 )
LCI' s 10-Year Price/Net Current Asset Value Range
Min: 3.82   Max: 670
Current: 9.71

3.82
670
Price/Tangible Book 5.90
LCI's Price/Tangible Book is ranked higher than
69% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.29 vs. LCI: 5.90 )
LCI' s 10-Year Price/Tangible Book Range
Min: 0.9   Max: 21.7
Current: 5.9

0.9
21.7
Price/DCF (Projected) 5.02
LCI's Price/DCF (Projected) is ranked higher than
80% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.24 vs. LCI: 5.02 )
LCI' s 10-Year Price/DCF (Projected) Range
Min: 0.57   Max: 5.86
Current: 5.02

0.57
5.86
Price/Median PS Value 3.89
LCI's Price/Median PS Value is ranked higher than
55% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. LCI: 3.89 )
LCI' s 10-Year Price/Median PS Value Range
Min: 0.42   Max: 6.89
Current: 3.89

0.42
6.89
Price/Peter Lynch Fair Value 0.73
LCI's Price/Peter Lynch Fair Value is ranked higher than
98% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. LCI: 0.73 )
LCI' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.5   Max: 15.96
Current: 0.73

0.5
15.96
Price/Graham Number 2.15
LCI's Price/Graham Number is ranked higher than
86% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.07 vs. LCI: 2.15 )
LCI' s 10-Year Price/Graham Number Range
Min: 0.93   Max: 6.23
Current: 2.15

0.93
6.23
Earnings Yield (Greenblatt) 9.50
LCI's Earnings Yield (Greenblatt) is ranked higher than
95% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. LCI: 9.50 )
LCI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 14.4
Current: 9.5

0.1
14.4
Forward Rate of Return (Yacktman) 55.95
LCI's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 527 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.94 vs. LCI: 55.95 )
LCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -15   Max: 115.5
Current: 55.95

-15
115.5

Analyst Estimate

Jun15 Jun16 Jun17
Revenue(Mil) 397 466 557
EPS($) 3.75 4.02 4.67
EPS without NRI($) 3.75 4.02 4.67

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:LN5.Germany,
Lannett Co Inc was incorporated in 1942 under the laws of the Commonwealth of Pennsylvania, and reincorporated in 1991 as a Delaware corporation. The Company develops, manufactures, markets and distributes generic versions of branded pharmaceutical products. The Company manufactures solid oral dosage forms, including tablets and capsules, extended release, topicals, oral solutions and distributes parenteral as well as ophthalmics. All of the products are currently manufactured and sold are prescription products. The Company's products containing Levo are produced and marketed with 12 varying potencies. In addition to generic Levo tablets, it also market and distribute Unithroid tablets, a branded version of Levo, which is produced and marketed with 11 varying potencies. Both generic Levo tablets and Unithroid tablets are manufactured by JSP. Lannett began buying generic Levo from JSP and selling it to its customers in April 2003. Levo tablets are used to treat hypothyroidism and other thyroid disorders. Levo remains the most prescribed drugs in the U.S. and is used by over 13 million patients of various ages and demographic backgrounds. In distribution of these products, the Company competes with two branded Levo products-Abbott Laboratories Synthroid(r) and Monarch Pharmaceuticals Levoxyl(r)- as well as generic products from Mylan and Sandoz. Digoxin tablets are produced and marketed with two different potencies, 0.125mg and 0.25mg per tablet. This product is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in September 2002. Digoxin tablets are used to treat congestive heart failure in patients of various ages and demographic backgrounds. The Company distributes two products containing Butalbital. Lannett has manufactured and sold one of the products, Butalbital with Aspirin and Caffeine capsules, for more than nine years. The other Butalbital product, Butalbital with Aspirin, Caffeine and Codeine Phosphate capsules, is manufactured by JSP. Lannett began buying this product from JSP and selling it to its customers in December 2002. Both Butalbital products, which are in orally administered capsule dosage forms, are prescribed to treat tension headaches caused by contractions of the muscles in the neck and shoulder area and migraine. Primidone tablets are produced and marketed with two different potencies, 50mg and 250mg tablets. Lannett has developed and manufacture Primidone tablets and began selling Primidone 50mg tablets in June 2001. In addition, the Company has been manufacturing and selling Primidone 250mg tablets for more than seven years. Both Primidone products, which are in orally administered tablet dosage forms, are prescribed to treat convulsion and seizures in epileptic patients of all ages and demographic backgrounds. Lannett sell its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, ma
» More Articles for NYSE:LCI

Headlines

Articles On GuruFocus.com
My Stocks Feb 13 2015 
My Stocks Feb 13 2015 
Lannett Company Looks Cheap At First Glance; But It Is Actually Much Cheaper Than It Looks Dec 29 2014 
comment on LCI Nov 19 2012 
comment on LCI Nov 13 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 26 2012 
comment on LCI Jan 23 2012 
comment on LCI Jan 23 2012 
Lannett Company Inc Reports Operating Results (10-Q) Nov 12 2010 


More From Other Websites
Akorn, Avago Lead IBD 50 Stocks In Earnings Growth Feb 28 2015
Stocks Slip, But Tumi Briefly Clears Buy Point Feb 27 2015
Strength Seen in ArQule (ARQL): Stock Soars 19.4% - Tale of the Tape Feb 27 2015
Lannett to Present at the 27th Annual ROTH Conference on March 9 Feb 27 2015
LANNETT CO INC Files SEC form 8-K, Regulation FD Disclosure Feb 26 2015
United Therapeutics Beats on Q4 Earnings & Revenues - Analyst Blog Feb 25 2015
Pacira Misses Earnings Estimates in Q4, Revenues In Line - Analyst Blog Feb 25 2015
Merck Strikes Deal with NGM to Develop Novel Biologics - Analyst Blog Feb 24 2015
Novartis' Farydak Approved for Multiple Myeloma with Warning - Analyst Blog Feb 24 2015
Lannett Joins Big-Game Hunt For Drugmaker Acquisitions Feb 24 2015
Lannett to Present at the RBC Capital Markets 2015 Healthcare Conference on February 24 Feb 24 2015
Five Top-Rated Medical Stocks To Keep Monitoring Feb 23 2015
Novo Nordisk's Oral Semaglutide Positive in Diabetes Study - Analyst Blog Feb 23 2015
Stocks Slip As Europe Weighs; Deere, Boise, Lannett Slide Feb 20 2015
Nasdaq Climbs Modestly As Indexes Close Mixed Feb 19 2015
Oncolytics Biotech Completes Enrolment for Reolysin Study - Analyst Blog Feb 19 2015
Actavis Tops Views, Announces Name Change To Allergan Feb 18 2015
Celsus Plunges on Dismal Dermatology Drug Study Results - Analyst Blog Feb 18 2015
Ignyta's Lead Drug Gets Orphan Status for Colorectal Cancer - Analyst Blog Feb 18 2015
Hot Stock Lannett Breaks Out; Vasco Can't Get Moving Feb 17 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK